Specify a stock or a cryptocurrency in the search bar to get a summary
CalciMedica, Inc. Common Stock
CALCCalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California. Address: 505 Coast Boulevard South, La Jolla, CA, United States, 92037
Analytics
WallStreet Target Price
17 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CALC
Dividend Analytics CALC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CALC
Stock Valuation CALC
Financials CALC
Results | 2019 | Dynamics |